Dear Colleagues,

Several new technologies and medications have been introduced for the treatment and prevention of cardiovascular (CV) disease over the past recent years. Despite this, the high incidence of ischemic events is still a major concern in modern medicine and is responsible for a large number of hospitalizations and deaths worldwide. Antiplatelet therapy is key to reducing ischemic events amongst patients with CV disease, but is inevitably associated with increased bleeding. A better understanding of the prognostic implications associated with bleeding, together with the reduced thrombogenicity of stent platforms and devices, have led to a substantial evolution in antiplatelet treatment regimens over the past decades. Numerous studies have been conducted to better stratify patients with CV disease according to their ischemic and bleeding risks and to then implement antithrombotic regimens accordingly. Evidence from this research has led to the development of several antithrombotic treatment options, as recommended by recent Guidelines.

Suggested sub-topics
- Strategies for prevention and management of bleeding among patients with cardiovascular disease
- Tailoring antiplatelet therapy in patients undergoing PCI: current evidence and practical recommendations

Dr. Domenico D'Amario and Dr. Mattia Galli
Guest Editors